Tacalyx

Berlin, Germany

Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.

$7.5M raised

Apr 2026

Seed

Top Investors

HTGF (High-Tech Gruenderfonds)Kurma PartnersEurazeoBoehringer Ingelheim Venture FundIdinvest Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Tacalyx raised?

Tacalyx has raised $7.5M in total funding. The most recent round was Seed. The last funding was announced in April 2026.

Who are Tacalyx's investors?

Tacalyx's investors include HTGF (High-Tech Gruenderfonds), Kurma Partners, Eurazeo, Boehringer Ingelheim Venture Fund, Idinvest Partners.

Where is Tacalyx headquartered?

Tacalyx is headquartered in Berlin, Germany.

What does Tacalyx do?

Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.

What stage is Tacalyx at?

Tacalyx is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 29, 2026.

MLA

"Tacalyx — Funding & Investors." VCBacked, April 29, 2026, https://www.vcbacked.co/company/tacalyx. Accessed June 3, 2026.

APA

VCBacked. (2026). Tacalyx — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/tacalyx

Wikipedia (cite web)

{{cite web |title=Tacalyx — Funding & Investors |url=https://www.vcbacked.co/company/tacalyx |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 29, 2026.